Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: Evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern

Journal of Molecular Neuroscience

Volumn 53, Issue 3, 2014, Pages 500-505

  Jafarzadeh, A ^a,b,c   Bagherzadeh, S ^b   Ebrahimi, H A ^a   Hajghani, H ^b   Bazrafshani, M R ^b   Khosravimashizi, A ^b   Nemati, M ^b   Gadari, F ^a   Sabahi, A ^a   Iranmanesh, F ^a   Mohammadi, M M ^b   Daneshvar, H ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CCL20; Gene polymorphism; Multiple sclerosis; Treatment

Indexed keywords

BETA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; METHYLPREDNISOLONE; CCL20 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; PROMOTER REGION; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; SEX DIFFERENCE;

ADULT; CASE-CONTROL STUDIES; CHEMOKINE CCL20; FEMALE; HUMANS; INTERFERON-BETA; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 84905040222     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-0214-2     Document Type: Article

References (25)

1. Ambrosini E, Columba-Cabezas S, Serafini B, Muscella A, Aloisi F (2003) Astrocytes are the major intracerebral source of macrophage inflammatory protein-3alpha/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. Glia 41:290-300 (Pubitemid 36258473)
2. Anlar O (2009) Treatment ofmultiple sclerosis. CNS Neurol Disord Drug Targets 8:167-174
3. Buc M (2013) Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis. Mediators Inflamm 2013:963748
4. Christensen JR, Bornsen L, Ratzer R, Piehl F, Khademi M, Olsson T, Sorensen PS, Sellebjerg F (2013) Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One 8:e57820
5. Hoglund RA, Holmoy T, Harbo HF, Maghazachi AA (2013) A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA). PLoS One 8:e62237
6. Holman DW, Klein RS, Ransohoff RM (2011) The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta 1812:220-230
7. Jadidi-Niaragh F, Mirshafiey A (2011) Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol 74:1-13
8. Kalinowska-Lyszczarz A, Szczucinski A, Pawlak MA, Losy J (2011) Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patients. J Neurol Sci 300:81-85
9. Kallaur AP, Oliveira SR, Colado Simao AN, Delicato de Almeida ER, Kaminami Morimoto H, Lopes J, de Carvalho Jennings Pereira WL, Marques Andrade R, Muliterno Pelegrino L, Donizete Borelli S, Kaimen-Maciel DR, Reiche EM (2013) Cytokine profile in relapsingremitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep 7:1010-1020
10. Kuchroo VK, Awasthi A (2012) Emerging new roles of Th17 cells. Eur J Immunol 42:2211-2214
11. Lee AY, Eri R, Lyons AB, Grimm MC, Korner H (2013) CC Chemokine Ligand 20 and Its Cognate Receptor CCR6 in Mucosal T Cell Immunology and Inflammatory Bowel Disease: Odd Couple or Axis of Evil? Front Immunol 4:194
12. Maddur MS, Miossec P, Kaveri SV, Bayry J (2012) Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 181:8-18
13. Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, Murai H, Kira J (2013) Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 8:e61835
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
15. Meares GP, Ma X, Qin H, Benveniste EN (2012) Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 60:771-781
16. Raman D, Sobolik-Delmaire T, Richmond A (2011) Chemokines in health and disease. Exp Cell Res 317:575-589
17. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F (2009) C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10:514-523
18. Rentzos M, Nikolaou C, Rombos A, Evangelopoulos ME, Kararizou E, Koutsis G, Zoga M, Dimitrakopoulos A, Tsoutsou A, Sfangos C (2008) Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. Clin Neurol Neurosurg 110:992-996
19. Rodgers JM, Miller SD (2012) Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J Biol Med 85:447-468
20. Rostami A, Ciric B (2013) Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci 333(1-2):76-87. doi:10.1016/j.jns.2013. 03.002
21. Szczucinski A, Kalinowska A, Losy J (2007) CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone. Eur Neurol 58:228-232 (Pubitemid 350175891)
22. Tesmer LA, Lundy SK, Sarkar S, Fox DA (2008) Th17 cells in human disease. Immunol Rev 223:87-113 (Pubitemid 351986173)
23. Wang X, Ma C, Wu J, Zhu J (2013) Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barre syndrome as well as their animal models. J Neurosci Res 91:871-881
24. Zhang W, Nie L, Wang Y, Wang XP, Zhao H, Dongol S, Maharjan S, Cheng L (2013) CCL20 Secretion from the Nucleus Pulposus Improves the Recruitment of CCR6-Expressing Th17 Cells to Degenerated IVD Tissues. PLoS One 8:e66286
25. Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, Iwakura Y, Mizuno T, Suzumura A (2011) IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol 186:4415-4421